Is NDRA a good buy?

**ENDRA Life Sciences (NDRA) presents a mixed outlook for investors to consider before making a purchase decision**: 1. **Technical Indicators Show Weakness**: The stock's closing price is at $3.36, with resistance at $5.08 and support at $3.02. Technical indicators such as MACD (-0.09), RSI (53.31), and KDJ (17.88) suggest the stock is neither overbought nor oversold. However, the BOLL indicator shows a value of $3.99, which the stock is currently trading below, indicating a potential for price movement upwards. |code|Ticker|Name|Date|Boll|RSI|KDJ|MACD|market_code| |---|---|---|---|---|---|---|---|---| |NDRA|NDRA.O|Endra Life Sciences|20250417|3.9875|53.3097|17.8804|-0.0882|186| |code|Ticker|Name|Date|Closing Price|Support Level|Resistance Level|market_code| |---|---|---|---|---|---|---|---| |NDRA|NDRA.O|Endra Life Sciences|20250417|3.36|3.3500|3.8900|186| 2. **Strategic Pivot**: The company has announced a strategic pivot towards early detection and management of metabolic diseases facilitated by emerging GLP-1 therapies. This shift could position NDRA well in a growing market, but it also comes with execution risks and the need for significant investment in research and development. 3. **Financial Health Concerns**: ENDRA Life Sciences has a history of negative earnings and did not generate any revenue during the years ended December 31, 2024, and 2023. The company reported a net loss of $11.51 million for the year ended December 31, 2024, and has acknowledged the need to raise additional capital to continue its operations. These financial indicators are a red flag for investors looking for profitability. 4. **Market Opportunity**: Despite the challenges, ENDRA Life Sciences is targeting a large market opportunity in the metabolic health sector, which affects over two billion people globally. The company's TAEUS system is envisioned as a simple, inexpensive tool for steatotic liver disease assessment and management, which could be a significant market need. 5. **Stock Market Dynamics**: The reverse stock split implemented by the company may be a sign of efforts to meet regulatory requirements and improve the stock's price, which could be a positive or negative signal depending on the outcome. The company has also been granted an extension to regain compliance with Nasdaq's minimum bid price requirement, which could be a positive development. In conclusion, while NDRA's strategic pivot and market opportunity are positive factors, the lack of revenue, negative earnings, and financial health concerns make it a risky investment. Investors should carefully weigh these factors and consider their risk tolerance before deciding whether NDRA is a good buy for them.